Subscribe
shutterstock_1635580639_sundry_photography
Sundry Photography / Shutterstock.com
27 February 2020AmericasSarah Morgan

Genentech in $1.7bn immuno-oncology deal

California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Roche and Innovent unite in $2bn biospecifics deal
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
Big Pharma
Genentech enters agreement to develop autoimmune therapies
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Asia-Pacific
Roche and Innovent unite in $2bn biospecifics deal
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
Big Pharma
Genentech enters agreement to develop autoimmune therapies
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

More on this story

Asia-Pacific
Roche and Innovent unite in $2bn biospecifics deal
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
Big Pharma
Genentech enters agreement to develop autoimmune therapies
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB